Actively Recruiting
Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project
Led by University Hospital, Brest · Updated on 2026-04-03
100
Participants Needed
2
Research Sites
257 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Brest
Lead Sponsor
U
University Hospital, Bordeaux
Collaborating Sponsor
AI-Summary
What this Trial Is About
The pathophysiology of certain inflammatory arthritides remains poorly understood, particularly when associated with rare systemic autoimmune diseases such as systemic sclerosis (SSc), or when emerging in the context of immune-related adverse events from cancer immunotherapies. These immunotherapy-induced arthritides represent a new and increasingly encountered clinical entity in rheumatology. A deeper understanding of the mechanisms underlying joint inflammation in these settings is essential for identifying specific therapeutic targets, especially given the limitations of current treatment options and the risks associated with broad immunosuppressive strategies such as prolonged corticosteroid use, which may impair anti-tumor immune responses. Synovial biopsy analysis provides a powerful tool for dissecting the cellular and molecular components of joint inflammation, including immune cell infiltration, cytokine profiles, and cell-cell interactions. Advances in high-dimensional techniques such as multiplex immunofluorescence and mass cytometry now allow for the identification and spatial localization of numerous protein markers at the subcellular level. Additionally, spatial transcriptomics offers complementary insight into gene expression profiles within the tissue microenvironment, providing a comprehensive understanding of inflammatory processes. The investigators propose a prospective, proof-of-concept study to characterize and compare rare and emerging inflammatory arthritides-including those linked to SSc and immunotherapy-related immune toxicity-with classical inflammatory rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), polymyalgia rheumatica (PMR), and reactive arthritis. Through detailed immunological and molecular profiling, this study aims to identify disease-specific signatures and novel therapeutic targets. These findings could pave the way for precision medicine approaches and inform the development of targeted therapies in both rare and common forms of inflammatory arthritis.
CONDITIONS
Official Title
Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed consent form
- Patients over 18 years old
- Affiliated with a social security scheme
- For rare arthritis cases: arthritis or bursitis linked to rare systemic autoimmune disease or drug-induced toxicity
- At least one clinical arthritis with synovial thickening confirmed by ultrasound (grade 2 in B-mode) and Doppler inflammation grade 1, or synovial thickening 2 with joint effusion
- For bursitis: thickening 2mm of at least one periarticular bursa on ultrasound with Doppler inflammation grade 1, or synovial thickening 2mm with joint effusion and clinical inflammatory signs
- For control group arthritis: clinical arthritis with ultrasound-confirmed synovial thickening and Doppler inflammation, diagnosed as rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, or reactive arthritis
- For control bursitis: thickening 2mm of periarticular bursa with Doppler inflammation or synovial thickening with joint effusion, meeting polymyalgia rheumatica criteria
You will not qualify if you...
- Under protective measures or unable to consent
- Pregnant or breastfeeding women
- Using anticoagulants including vitamin K antagonists, direct oral anticoagulants, or curative dose heparins
- Contraindications to local procedure such as lymphedema near joint, chronic wound at joint site, joint prosthesis on affected joint, or corticosteroid infiltration less than 3 months ago at same site
- History of biotherapy or targeted therapy (JAK inhibitors) within last 3 months or Rituximab within last 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHU bordeaux
Bordeaux, France, 33404
Not Yet Recruiting
2
CHU Brest - Hôpital Morvan
Brest, France, 29200
Actively Recruiting
Research Team
A
Alice Tison, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here